Business
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
OSAKA, Japan, May 08, 2025--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/03778ddead0955228d60333db7dc62ee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sOKcqPKQXf.d8d5bZQ5aVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/03778ddead0955228d60333db7dc62ee","width":480,"height":320}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024","length":108,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings","length":88,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation","length":135,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Proposed Dividend Increase from JPY 196 to JPY 200","length":50,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":513,"olType":false},{"type":"text","content":"OSAKA, Japan, May 08, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.","length":347,"tagName":"p"},{"type":"text","content":"Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year.","length":298,"tagName":"p"},{"type":"text","content":"FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE® generic impact, continued efficiency ...